What the oral trial measured
Our review of alcohol and tirzepatide addresses a different drug and a different question. The trial here tested semaglutide for alcohol use disorder.
Schacht and colleagues randomized 50 treatment-seeking adults to oral semaglutide or placebo for eight weeks. At week six, the groups did not differ significantly on the primary craving measure after exposure to a preferred drink. The adjusted difference was −0.614 points (95% confidence interval −3.563 to 2.335) [1].
In the last four weeks, the semaglutide group reported fewer heavy drinking days on a prespecified secondary outcome. The adjusted model coefficient was −0.580 (95% confidence interval −1.012 to −0.148). The difference in drinks per calendar day did not reach statistical significance [1].
Drinks per drinking day and craving in daily life fell on exploratory measures. The trial used a different questionnaire for daily craving than for the primary laboratory measure. The researchers reported confidence intervals without adjusting for multiple comparisons, so the exploratory findings need confirmation [1].
What the injection trial adds
A separate trial recruited 108 adults with alcohol use disorder and obesity. Both groups received cognitive behavioral therapy. After 26 weeks, the share of heavy drinking days fell 13.7 percentage points more with weekly semaglutide injections than with placebo (95% confidence interval 5.4 to 22.0 points more)[2].
Studies of GLP-1 medicines for opioid use disorder ask a different treatment question and use different outcome measures. Even within alcohol research, the injection trial measured heavy drinking days in adults with obesity and the oral trial prioritized a craving score. The two trials cannot establish whether one formulation works better for alcohol use disorder.
The oral trial followed participants for only eight weeks. Its results leave open whether any effect persists on longer treatment or after stopping [1].